The objective of this study was to use a 72-gene panel,[21] which contains the 17 immunity genes, 19 proliferation genes, 11 Basal genes, 14 ER genes, 3 HER2E genes, 2 invasion genes, and 6 housekeeper genes, to assess their distribution and association with the efficacy of neoadjuvant chemotherapy plus trastuzumab of patients with nonmetastatic HER2-positive breast cancer who failed to achieved pCR after neoadjuvant therapy. The gene discussed is ERBB2; the disease is breast cancer.